Duality Biologics

Duality Biologics (DualityBio) is a leading clinical-stage biotechnology company specializing in the discovery and development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary technology platforms, including DITAC (Duality Immune Toxin Antibody Conjugate) and DIMAC (Duality Immune Modulating Antibody Conjugate), to develop a robust pipeline of 'Super ADCs' designed to provide superior efficacy and safety profiles compared to traditional therapies. Headquartered in Shanghai with a significant clinical and business presence in Princeton, New Jersey, DualityBio has rapidly expanded its global footprint through high-value strategic partnerships with major pharmaceutical players like BioNTech and GSK. The company successfully transitioned to a public entity in April 2025, listing on the Hong Kong Stock Exchange, and continues to advance multiple late-stage clinical programs targeting high-incidence solid tumors.